Tumour angiogenesis: vascular growth and survival

Angiogenesis starts at the edge of a malignant epithelial tumour concurrently with tumour cell invasion and stromatogenesis, i.e. the formation of specific connective tissue stroma amenable to easy penetration by endothelial and tumour cells. However, as the tumour continues its growth, the edge becomes the inner tumour area, and a new invading tumour front is formed by the multiplying malignant cells which outflank the initial edge. This process, which repeats itself again and again, forms the “relay race” model of tumour vascular growth and regression. At the heart of the tumour unfavourable environmental conditions prevail – hypoxia, acidity, lack of nutrients, failure of waste removal, and apoptosis rather than proliferation. Blood vessels and tumour cells are greatly decreased, but do not vanish, as tumour cells are shifting to anaerobic glycolysis, and blood vessels are turning into anti‐apoptotic pathways – vascular survival ability (VSA). Thus, assessing vascular density (VD) by simply counting “hot spots” at the edge of a tumour, where conditions are most favourable, is futile; it may reflect tumour angiogenic activity (TAA), but is not representative of genuine tumour vasculature. By combining vessel counts at the invading tumour front with those of the inner tumour areas a complete picture of tumour VD can be achieved. The thus formed four patterns of vascularization, designated as “edvin” (edge vsinner tumour area), are: edvin 1: low TAA/low VSA; edvin 4: high TAA/high VSA; edvin 2: low TAA/high VSA; and edvin 3: high TAA/low VSA. It is expected that this scheme will prove useful in the field of chemoradiotherapy and anti‐angiogenic treatment.

[1]  A. Giatromanolaki,et al.  Tumour angiogenic activity and vascular survival ability in bladder carcinoma , 2004, Journal of Clinical Pathology.

[2]  D. Mavroudis,et al.  Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse , 2004, International journal of cancer.

[3]  A. Giatromanolaki,et al.  “Stromatogenesis” and Tumor Progression , 2004, International journal of surgical pathology.

[4]  J. Christensen,et al.  c-Met: Structure, functions and potential for therapeutic inhibition , 2003, Cancer and Metastasis Reviews.

[5]  A. Giatromanolaki,et al.  The vascular network of tumours — what is it not for? , 2003, The Journal of pathology.

[6]  A. Giatromanolaki,et al.  Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis , 2003, British Journal of Cancer.

[7]  A. Harris,et al.  Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer , 2003, The Journal of pathology.

[8]  A. Harris,et al.  Hypoxia‐induced pathways in breast cancer , 2002, Microscopy research and technique.

[9]  Y. Taniyama,et al.  Hepatocyte growth factor prevents endothelial cell death through inhibition of bax translocation from cytosol to mitochondrial membrane. , 2002, Diabetes.

[10]  P. Pedersen,et al.  Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. , 2002, Cancer research.

[11]  G. Yancopoulos,et al.  Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. , 2002, Microvascular research.

[12]  C. Simopoulos,et al.  Differential assessment of vascular survival ability and tumor angiogenic activity in colorectal cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  A. Harris,et al.  Angiogenic co‐operation of VEGF and stromal cell TP in endometrial carcinomas , 2002, The Journal of pathology.

[14]  C. Simopoulos,et al.  Prognostic Role of Angiogenesis in Operable Carcinoma of the Gallbladder , 2002, American journal of clinical oncology.

[15]  D. Tsiftsis,et al.  The role of 99mTc-sestamibi scintimammography and colour Doppler ultrasonography in the evaluation of breast lesions , 2001, Nuclear medicine communications.

[16]  M. Koukourakis Tumour angiogenesis and response to radiotherapy. , 2001, Anticancer research.

[17]  D. Bouchier-Hayes,et al.  Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells , 2001, British Journal of Cancer.

[18]  I. Zachary Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. , 2001, American journal of physiology. Cell physiology.

[19]  N. Savaraj,et al.  Hypersensitization of tumor cells to glycolytic inhibitors. , 2001, Biochemistry.

[20]  W. Sessa,et al.  Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. , 2001, The American journal of pathology.

[21]  P Vaupel,et al.  Biological consequences of tumor hypoxia. , 2001, Seminars in oncology.

[22]  W. Thompson Tumour versus patient: vascular and tumour survival versus prognosis. , 2001, The Journal of pathology.

[23]  R. D. de Waal,et al.  Lymphangiogenesis in malignant tumours: does it occur? , 2001, The Journal of pathology.

[24]  A. Harris,et al.  ‘Invading edge vs. inner’ (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non‐small cell lung cancer , 2000, The Journal of pathology.

[25]  A. Giatromanolaki,et al.  Cancer vascularization: implications in radiotherapy? , 2000, International journal of radiation oncology, biology, physics.

[26]  H. Nishimatsu,et al.  Adrenomedullin and nitric oxide inhibit human endothelial cell apoptosis via a cyclic GMP-independent mechanism. , 2000, Hypertension.

[27]  A. Harris,et al.  Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. , 2000, Cancer research.

[28]  K. Hörmann,et al.  Expression of basic fibroblast growth factor protein and its down‐regulation by interferons in head and neck cancer , 2000, Head & neck.

[29]  A. Giatromanolaki,et al.  Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  G. Lapin,et al.  Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. , 1999, Microvascular research.

[31]  A. Harris,et al.  Combined role of tumor angiogenesis, bcl‐2, and p53 expression in the prognosis of patients with colorectal carcinoma , 1999, Cancer.

[32]  A. Harris,et al.  Thymidine phosphorylase expression in endometrial carcinomas , 1999, Clinical & Experimental Metastasis.

[33]  A. Harris,et al.  Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer , 1999, International journal of cancer.

[34]  J. Martin,et al.  VEGF modulates NO production: the basis of a cytoprotective effect? , 1999, Cardiovascular research.

[35]  A. Giatromanolaki,et al.  Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  A. Miodoński,et al.  Vascular architecture of human urinary bladder carcinoma: a SEM study of corrosion casts , 1998, Virchows Archiv.

[37]  R. Brekken,et al.  Vascular endothelial growth factor as a marker of tumor endothelium. , 1998, Cancer research.

[38]  R. Shivers,et al.  Quantitative comparison of the morphology of the microvasculature of primary lung lesions and metastatic brain tumours. , 1998, Journal of submicroscopic cytology and pathology.

[39]  C. Dang,et al.  A unique glucose-dependent apoptotic pathway induced by c-Myc. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  K. O'Byrne,et al.  Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. , 1997, British Journal of Cancer.

[41]  L. Ellis,et al.  Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. , 1996, Journal of the National Cancer Institute.

[42]  S. Fox,et al.  TUMOUR ANGIOGENESIS , 1996, The Journal of pathology.

[43]  A. Harris,et al.  PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON‐SMALL CELL LUNG CANCER , 1996, The Journal of pathology.

[44]  M. Toi,et al.  Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  A. Harris,et al.  Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  R. Whyte,et al.  Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma , 1994, The Journal of experimental medicine.

[47]  R Bicknell,et al.  Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. , 1993, Cancer research.

[48]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[49]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[50]  W. Thompson,et al.  Tumours acquire their vasculature by vessel incorporation, not vessel ingrowth , 1987, The Journal of pathology.

[51]  R. Jain Transport of Macromolecules In Tumor Microcirculation , 1985, Biotechnology progress.

[52]  J. Vane,et al.  Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. , 1978, Prostaglandins.

[53]  F. Cajone,et al.  Anaerobic glycolysis and patterns of glycolytic intermediates during liver carcinogenesis and in hepatoma. , 1970, Journal of the National Cancer Institute.

[54]  A. Harris,et al.  Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer , 2004, Clinical & Experimental Metastasis.

[55]  M. Toi,et al.  Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression , 2004, Breast Cancer Research and Treatment.

[56]  Rakesh K. Jain,et al.  Transport of molecules across tumor vasculature , 2004, Cancer and Metastasis Reviews.

[57]  G. Semenza,et al.  'The metabolism of tumours': 70 years later. , 2001, Novartis Foundation symposium.

[58]  A. Giatromanolaki,et al.  Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer. , 2000, Oncology research.

[59]  A. Giatromanolaki,et al.  Intratumoral angiogenesis: a new prognostic indicator for stage I endometrial adenocarcinomas? , 1999, Oncology research.